Genentech Herceptin "Fast-Track" Review Aided By Rolling BLA
Executive Summary
The "fast-track" review of Genentech's Herceptin has been aided by pre-submission of parts of the BLA as part of a rolling application, Genentech Regulatory Affairs Advisor David MacFarlane, PhD, told the Food & Drug Law Institute July 14 in Washington D.C.